drugset / Trial / NCT05069870
A Study to Investigate the Drug-drug Interactions (DDIs) of SKLB1028 With Itraconazole, Gemfibrozil or Rifampicin in Healthy Subjects
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a three-part, single-center, open-label phase I clinical study to characterize the DDIs potential of SKLB1028 with Itraconazole, Gemfibrozil or Rifampicin in healthy subjects. This study also aims to evaluate the safety and tolerability of SKLB1028 in the presence of Itraconazole, Gemfibrozil or Rifampicin.
Timeline
- Start
- 2021-06-07
- Primary completion
- 2021-11
- Completion
- 2021-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemfibrozil | Small molecule | 600 mg | Oral |
| Subject | Itraconazole | Small molecule | 200 mg | Oral |
| Subject | RUSERONTINIB | Small molecule | 100 mg | Oral |
| Subject | RUSERONTINIB | Small molecule | 150 mg | Oral |
| Subject | Rifampin | Small molecule | 600 mg | Oral |
Indications
No indication recorded.